James Sandy

Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy.

Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom.

Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Ellipses Pharma Ltd. engages in the development of cancer medicines and treatment drugs. The company was founded by Christopher Evans and Rajan Jethwa in April 14, 2015 and is headquartered in London, the United Kingdom.